This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is the Future Bleak for SAVA Stock Following Another Setback?
by Zacks Equity Research
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
by Zacks Equity Research
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
by Zacks Equity Research
SAVA and APLT tank on pipeline and regulatory setbacks.
A Post-Mortem on Cassava Sciences
by David Bartosiak
This was a stock that traded above $140 a few short years ago. Now, it's all blown-up, leaving investors wondering why.
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
by Zacks Equity Research
Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
by Zacks Equity Research
Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.
What Makes Cassava Sciences (SAVA) a New Buy Stock
by Zacks Equity Research
Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
Company News for Sep 30, 2024
by Zacks Equity Research
Companies In The Article Are:BMY, SAVA, SATS, COST
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
by Zacks Equity Research
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Brian's Big Idea on Low Priced Stocks
by Brian Bolan
A look at low priced stocks and the Stocks Under $10 Service.
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
by Zacks Equity Research
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.